Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | HRH2 | P25021 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | SCN1A | P35498 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2310585 | 0.98 | POLB (0.62) | POLBSCN5AABCB11CYP3A4ADRA2B | |
| SCHEMBL29114255 | 0.98 | POLB (0.62) | POLBSCN5AABCB11CYP3A4ADRA2B | |
| SCHEMBL11560046 | 0.98 | POLB (0.62) | POLBSCN5AABCB11CYP3A4ADRA2B | |
| SCHEMBL11565392 | 0.98 | POLB (0.62) | POLBSCN5AABCB11CYP3A4ADRA2B | |
| SCHEMBL11560232 | 0.98 | POLB (0.62) | POLBSCN5AABCB11CYP3A4ADRA2B | |
| SCHEMBL11075289 | 0.98 | POLB (0.62) | POLBSCN5AABCB11CYP3A4ADRA2B | |
| SCHEMBL11564179 | 0.98 | POLB (0.62) | POLBSCN5AABCB11CYP3A4ADRA2B | |
| SCHEMBL14149520 | 0.95 | SCN5A (0.68) | POLBSCN5AABCB11CYP3A4ADRA2B | |
| SCHEMBL5925515 | 0.88 | POLB (0.70) | POLBSCN5AABCB11CYP3A4ADRA2B | |
| SCHEMBL11496351 | 0.87 | POLB (0.54) | POLBSCN5AABCB11CYP3A4ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025086591-A1 | ROTIGOTINE PRODRUG DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 烟台药物研究所 | 2025-05-01 | — | — | WO | disclosed |
| CN-117105906-B | Rotigotine prodrug derivatives, pharmaceutical compositions and uses thereof | 烟台药物研究所 | 2024-01-30 | — | — | CN | disclosed |
| CN-117105906-A | Rotigotine prodrug derivatives, pharmaceutical compositions and uses thereof | 烟台药物研究所 | 2023-11-24 | — | — | CN | disclosed |
| EP-1430023-B1 | SUBSTITUIED UREA RETINOID AGONISTS II | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-6838472-B2 | For treating or preventing emphysema, cancer and dermatological disorders | SYNTEX (U.S.A.) LLC (US) | 2005-01-04 | — | — | US | disclosed |
| EP-1430023-A1 | SUBSTITUIED UREA RETINOID AGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-23 | — | — | EP | disclosed |
| US-20030125383-A1 | Substituted urea retinoid agonists | ROCHE BIOSCIENCE, A DIVISION OF SYNTEX (U.S.A.) LLC | 2003-07-03 | — | — | US | disclosed |
| EP-1299350-A1 | SUBSTITUTED BENZAMIDES FOR IMMUNE ENHANCEMENT AND FOR THE TREATMENT OF CANCER, INFECTION AND MANIC-DEPRESSIVE ILLNESS | Active Biotech AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2003024920-A1 | SUBSTITUTED UREA RETINOID AGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002002511-A1 | SUBSTITUTED BENZAMIDES FOR IMMUNE ENHANCEMENT AND FOR THE TREATMENT OF CANCER, INFECTION AND MANIC-DEPRESSIVE ILLNESS | ACTIVE BIOTECH AB (SE) | 2002-01-10 | — | — | WO | disclosed |
| EP-0425921-B1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-5250554-A | Cardiovascular disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-05 | — | — | US | disclosed |
| US-5128356-A | Angiotensin antagonist; cardiovascular disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-07-07 | — | — | US | disclosed |
| EP-0425921-A1 | Benzimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125383-A1 | Substituted urea retinoid agonists | RXRA, RXRG, RARG | POLB 1686/4885SCN5A 4563/4885ABCB11 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.